tiprankstipranks
Trending News
More News >
Lyra Therapeutics, Inc. (LYRA)
:LYRA
US Market
Advertisement

Lyra Therapeutics (LYRA) AI Stock Analysis

Compare
364 Followers

Top Page

LYRA

Lyra Therapeutics

(NASDAQ:LYRA)

Rating:46Neutral
Price Target:
$7.00
▲(2.49% Upside)
Lyra Therapeutics' overall stock score reflects significant financial struggles and weak technical indicators. However, recent corporate achievements and strategic plans offer some optimism for future growth, notably in the biotechnology sector's volatile environment.
Positive Factors
Clinical Trial Success
The ENLIGHTEN-2 trial achieved its primary endpoint with statistically significant improvement in the composite of the three cardinal symptoms of chronic rhinosinusitis for patients without nasal polyps.
Regulatory Alignment
Lyra Therapeutics is aligned with the FDA on prospective pivotal Phase 3 development in non-polyp patients, pending the ENLIGHTEN-2 outcome and analysis.
Negative Factors
Clinical Trial Failure
The ENLIGHTEN-1 trial failed to demonstrate statistically significant CRS benefit, contrasting with the success of the ENLIGHTEN-2 trial.
Stock Market Compliance
The company announced plans to implement a reverse stock split to maintain compliance with NASDAQ listing standards.

Lyra Therapeutics (LYRA) vs. SPDR S&P 500 ETF (SPY)

Lyra Therapeutics Business Overview & Revenue Model

Company DescriptionLyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
How the Company Makes MoneyLyra Therapeutics primarily generates revenue through the development and potential commercialization of its therapeutic products. The company focuses on advancing its drug delivery platform and product candidates through clinical trials, seeking regulatory approvals to eventually bring these products to market. Revenue streams are expected to come from the sale of approved products, partnerships, and collaborations with other pharmaceutical companies, as well as potential licensing agreements. However, as a clinical-stage company, Lyra currently depends on funding from investors and strategic partnerships to finance its research and development activities until its products are commercially viable.

Lyra Therapeutics Financial Statement Overview

Summary
Lyra Therapeutics faces financial challenges, with consistent losses and negative cash flows. Despite some operational cash efficiency, the company's high leverage and shrinking equity base pose significant risks, necessitating strategic adjustments to improve profitability.
Income Statement
40
Negative
Lyra Therapeutics has experienced a decrease in total revenue from $1,558,000 in 2023 to $1,534,000 in 2024. The net profit margin remains negative, reflecting ongoing losses. Despite revenue growth in prior years, the company struggles with high operating losses, as evidenced by the negative EBIT and EBITDA margins.
Balance Sheet
45
Neutral
The company's debt-to-equity ratio has increased, indicating higher leverage, but remains manageable. Stockholders' equity has decreased significantly, suggesting potential financial instability. Despite a high equity ratio, the reduction in total assets and equity raises concerns about long-term sustainability.
Cash Flow
50
Neutral
Lyra has a negative free cash flow, indicating cash outflows exceeding inflows. Operating cash flow remains negative, though there is a high operating cash flow to net income ratio, reflecting cash efficiency in operations. However, the reliance on financing activities for cash inflows indicates a need for external funding.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.53M1.56M1.36M285.00K0.00
Gross Profit1.06M1.56M296.00K-716.00K-95.00K
EBITDA-60.26M-65.25M-53.92M-42.61M-22.11M
Net Income-93.44M-62.68M-55.28M-42.41M-22.05M
Balance Sheet
Total Assets66.35M142.60M109.97M54.87M80.83M
Cash, Cash Equivalents and Short-Term Investments40.58M102.75M97.89M45.75M74.59M
Total Debt34.38M26.88M2.22M1.45M2.44M
Total Liabilities54.75M53.18M29.21M20.55M6.34M
Stockholders Equity11.59M89.42M80.75M34.32M74.49M
Cash Flow
Free Cash Flow-72.35M-64.35M-43.55M-29.20M-22.92M
Operating Cash Flow-70.01M-63.30M-43.38M-25.82M-21.14M
Investing Cash Flow80.31M-12.58M-65.01M-3.38M-1.77M
Financing Cash Flow8.53M65.69M96.26M359.00K87.70M

Lyra Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price6.83
Price Trends
50DMA
10.59
Negative
100DMA
8.22
Negative
200DMA
9.28
Negative
Market Momentum
MACD
-0.89
Positive
RSI
35.98
Neutral
STOCH
17.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYRA, the sentiment is Negative. The current price of 6.83 is below the 20-day moving average (MA) of 7.94, below the 50-day MA of 10.59, and below the 200-day MA of 9.28, indicating a bearish trend. The MACD of -0.89 indicates Positive momentum. The RSI at 35.98 is Neutral, neither overbought nor oversold. The STOCH value of 17.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LYRA.

Lyra Therapeutics Risk Analysis

Lyra Therapeutics disclosed 87 risk factors in its most recent earnings report. Lyra Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Lyra Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
kr5.99B9.30-57.89%2.12%23.80%21.79%
46
Neutral
$10.79M-195.46%-29.46%2.71%
40
Underperform
$5.71M234.90%62.35%
35
Underperform
$5.70M-135.33%-51.32%-1.76%
34
Underperform
$5.57M-538.87%-26.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
LYRA
Lyra Therapeutics
6.75
-8.63
-56.11%
BCLI
Brainstorm Cell Therapeutics
0.58
-3.09
-84.20%
GTBP
GT Biopharma
1.77
-0.43
-19.55%
SPRB
Spruce Biosciences
0.14
-33.19
-99.58%

Lyra Therapeutics Corporate Events

Executive/Board Changes
Lyra Therapeutics Announces Leadership Changes in August 2025
Neutral
Aug 1, 2025

On August 1, 2025, Lyra Therapeutics announced the immediate termination of Dr. Harlan W. Waksal’s employment as Executive Chairman, following a mutual agreement. Dr. Waksal also resigned from the Board of Directors, and Maria Palasis, the company’s President and CEO, was appointed as the new Chair of the Board, while Jim Tobin continues as Lead Independent Director.

The most recent analyst rating on (LYRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.

Private Placements and FinancingBusiness Operations and Strategy
Lyra Therapeutics Secures $4.3M in Direct Offering
Neutral
Jun 27, 2025

On June 26, 2025, Lyra Therapeutics entered into a securities purchase agreement with accredited and institutional investors, resulting in a registered direct offering and concurrent private placement of shares and warrants, expected to yield approximately $4.3 million in net proceeds. The funds are intended for working capital and potential clinical development of LYR-210, reflecting the company’s strategic efforts to advance its product pipeline despite past challenges, including the failure to meet the primary endpoint in a Phase 3 clinical trial and significant workforce reductions.

The most recent analyst rating on (LYRA) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.

Delistings and Listing ChangesRegulatory Filings and Compliance
Lyra Therapeutics Regains Nasdaq Compliance in June 2025
Positive
Jun 23, 2025

On June 13, 2025, Lyra Therapeutics, Inc. received a notification from Nasdaq confirming that its common stock maintained a minimum bid price of $1.00 or more for 12 consecutive business days, from May 28, 2025, to June 12, 2025. This achievement means the company has regained compliance with Nasdaq’s Listing Rule 5550(a)(2), closing the matter.

The most recent analyst rating on (LYRA) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Lyra Therapeutics Unveils Strategic Plans for LYR-210
Positive
Jun 9, 2025

On June 9, 2025, Lyra Therapeutics announced the posting of a corporate presentation detailing their progress and strategic plans for LYR-210, following the successful ENLIGHTEN 2 Phase 3 trial. The company aims to advance LYR-210 for CRS with polyp indication, with a Phase 3 trial planned for early 2026, highlighting its commitment to addressing the needs of CRS patients and expanding its pipeline opportunities.

The most recent analyst rating on (LYRA) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Lyra Therapeutics Announces Positive Phase 3 Trial Results
Positive
Jun 2, 2025

On June 2, 2025, Lyra Therapeutics announced positive results from the ENLIGHTEN 2 Phase 3 clinical trial of LYR-210, which met its primary and key secondary endpoints for treating chronic rhinosinusitis (CRS) at 24 weeks. The trial demonstrated statistically significant improvements in symptoms for patients both with and without nasal polyps, positioning Lyra to advance regulatory strategies and potentially become a leader in CRS treatment.

The most recent analyst rating on (LYRA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.

Shareholder MeetingsStock Split
Lyra Therapeutics Announces Reverse Stock Split Decision
Neutral
May 19, 2025

On May 14, 2025, Lyra Therapeutics held its Annual Meeting of Stockholders where key decisions were made, including the election of two Class II Directors and the approval of a reverse stock split. The reverse stock split, set at a ratio of 1-for-50, will become effective on May 27, 2025, with trading on a split-adjusted basis commencing on May 28, 2025. This strategic move is aimed at consolidating shares to potentially enhance the stock’s marketability and meet trading requirements.

The most recent analyst rating on (LYRA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 31, 2025